000250

SCD is a pharmaceutical company established in 1943 that manufactures and sells prescription drugs, including antibiotics, cardiovascular treatments, gastrointestinal medications, and ophthalmic products. The company operates through a single business segment and produces its products at a facility in Hwaseong, South Korea. Its subsidiary Optus Pharmaceutical manufactures ophthalmic solutions and eye drops, while SCD US, INC and SCD BIOTECH, LLC handle export certifications and approvals in North America, and SCD JAPAN manages pharmaceutical wholesale in Japan. SCD exports finished pharmaceuticals to markets including Vietnam, Hong Kong, Singapore, the United States, and Europe. The company has established supply and distribution partnerships with Breckenridge Pharmaceutical, Glenmark, Omnivision, SENJU Pharmaceutical, Apotex, Fresenius Kabi, and Daiichi Sankyo. Its research and development portfolio includes the Aflibercept biosimilar SCD411 for macular degeneration, MRI contrast agents, and oral generic versions of diabetes and obesity treatments such as Rybelsus and Wegovy Oral.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Drug Manufacturers - General Homepage scd.co.kr
Sector Healthcare IR page —
Tags
ophthalmic drugs, antibiotics, cardiovascular drugs, gastrointestinal drugs, biosimilars, contrast agents, oral generics, diabetes treatment, obesity treatment, macular degeneration, Optus Pharmaceutical, SCD US INC, SCD BIOTECH LLC, SCD JAPAN, SCD411, SCD311, SCD0503, SCD0506, SCD0501, SCD0502, SCD0504, Aflibercept, Rybelsus, Wegovy Oral, S-Pass
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 1.9%
ROI 1.9%
ROIC 2.9%
Profit margin 2.3%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -3.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock —
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 231.805B 210.924B 192.669B 177.335B 167.275B 166.862B 186.602B 159.96B 161.112B 147.373B 132.062B 118.924B 104.543B
Net profit 5.262B -10.916B -10.383B 5.838B -16.555B -965.677M 10.452B 8.754B 15.058B 8.712B 11.628B 11.848B 8.724B
Free cash flow -36.353B 4.748B 16.662B -3.252B -22.589B -5.429B 24.009B 13.482B 25.378B 13.656B 8.688B 10.833B 11.657B

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 38.3B 38.9B 36.8B 38.5B 36.2B 34.2B 37.9B 34.4B 58.1B 55.3B
↳ YoY growth +18.2% +1.6% -5.4% +4.7% -6.0% -5.5% +10.8% -9.3% +68.9% -4.9%
↳ 5y CAGR +3.6% +2.9% +2.3% -2.2% -0.5% -1.3% +8.6% +8.8%
Borrowings, current (KRW) 6.98B 2.34B 13B 13.6B 2.01B 21.6B 2.76B 32.2B 28.3B 44.8B
Borrowings, non-current (KRW) — 3B — — 20B 26.1B 40B 16B 17B 0.00
Bonds payable (KRW) — — 10.8B 11.2B — 26.1B 27.8B 0.00 0.00 —
Lease liabilities (KRW) — — — 2.78B 5.06B 3.9B 6.01B 5.4B 4.65B 4.02B
Cash and deposits (KRW) 48.6B 61.9B 51.5B 60.3B 58.9B 49.1B 22.1B 40.4B 106B 95.9B
Intangible assets (KRW) 13.1B 20B — 30.2B — — — 96.3B — 130B
Net debt (borrowings + leases - cash) (KRW) -41.6B -56.6B -38.5B -43.9B -31.9B 2.43B 26.7B 13.2B -55.6B -47.1B
Cash flow detail
Operating cash flow (KRW) 17.8B 28.6B 25B 30.6B 3.25B -7.71B 13.3B 23.4B 21.8B 9.79B
Purchases of property, plant and equipment (KRW) -4.11B -3.25B -11.6B -6.59B -8.68B -14.9B -16.5B -6.77B -17B -46.1B
Purchases of intangible assets (KRW) -5B -7.6B -8.41B -3.57B -3.12B -14.4B -30B -15.2B -24.3B -13.4B
Change in receivables (cash effect) (KRW) — — — — — -2.35B -3.47B 3.21B -23.5B —
Change in inventories (cash effect) (KRW) -2.33B -3.46B -1.57B -1.62B -4B -2.28B -5.29B -5.75B -5.07B -15.8B
Change in payables (cash effect) (KRW) — — — — — 4.59B -3.69B -6.3B 13.2B 9.47B
Dividends paid (cash effect) (KRW) -2.02B -2.06B -2.07B -2.07B -2.07B -968M -968M -881M -890M -4.65B
Share buybacks (cash effect) (KRW) — — — — -2.02B 0.00 -5.96B 0.00 0.00 0.00
Interest paid (cash effect) (KRW) -124M -198M -222M -222M -173M -378M -1.37B -2.85B -128M -138M
Income taxes paid (cash effect) (KRW) -6.14B -4.28B -3.03B -2.03B -8.15B -3.28B -2.43B -1.43B -2.63B -22B
Share-based compensation (KRW) — — — — — 0.00 0.00 81.4M 519M -503M
Operating cash flow before change in receivables (KRW) — — — — — -5.36B 16.7B 20.2B 45.3B —
Free cash flow (OCF - PPE - intangibles) (KRW) 8.65B 17.8B 5.07B 20.4B -8.55B -37B -33.3B 1.45B -19.5B -49.8B
Income detail
Total comprehensive income (KRW) 15.8B 29.4B 14.1B 19.5B 7.87B -6.43B 9.4B -5.63B -5.43B 12.2B
Comprehensive income to owners (KRW) 8.97B 21.4B 8.25B 10.4B -823M -12.5B 6.41B -11.9B -11.1B 5.2B
Provision for credit losses (KRW) — — — — — -166M 246M 77.7M 266M 23.8M
Credit cost ratio (credit losses / average receivables) (%) — — — — — 0.5% 0.7% 0.2% 0.6% 0.0%
Reported Jun 18, 2018 Jun 18, 2018 Mar 29, 2019 Nov 16, 2020 Mar 15, 2021 Mar 20, 2024 Mar 20, 2024 Aug 14, 2024 May 15, 2025 Oct 8, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

분기보고서 (2026.09) Bull 0 Bear 0 Results
주식등의대량보유상황보고서(일반) Bull 0 Bear 0 Routine

Prompts

SCD (ticker 000250), listed in South Korea.

ETFs Holding SCD

ETF Weight in ETF Shares Market value As of
DFAE 0.01% 6,918 $ 947.393K Nov 12, 2026
DFSE 0.01% 397 $ 54.368K Nov 12, 2026
DEXC 0.01% 124 $ 16.981K Nov 12, 2026
DFEM 0.01% 3,874 $ 530.529K Nov 12, 2026
DFAX 0.00% 1,403 $ 192.135K Nov 12, 2026
AVEM 0.00% 1,941 $ 235.891K Nov 16, 2026